Understand the source comparison
FOXO4-DRI vs NAD+: Mechanism Comparison
Primary Mechanism Disrupts FOXO4-p53 interaction in senescent cells, inducing selective apoptosis Restores NAD+ levels to support redox reactions, sirtuin activity, and mitochondrial function Non-overlapping mechanisms. One eliminates dysfunctional cells, the
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- Primary Mechanism
- Disrupts FOXO4-p53 interaction in senescent cells, inducing selective apoptosis
- Restores NAD+ levels to support redox reactions, sirtuin activity, and mitochondrial function
- Non-overlapping mechanisms. One eliminates dysfunctional cells, the other sustains functional cells
- Target Cell Type
- Senescent cells (permanent growth arrest, SASP-positive)
- All metabolically active cells with functional mitochondria
- FOXO4-DRI selective for senescence; NAD+ acts broadly across healthy tissue
- Clinical Evidence
- Preclinical only. Mouse models show functional restoration (Erasmus 2017, Cell)
- Human Phase I/II trials show NAD+ restoration and improved metabolic markers (Elysium BASIS, ChromaDex NIAGEN studies)
- NAD+ precursors have significantly more human safety and efficacy data
- Mechanism of Action Timeline
- Hours to days. Apoptosis induction in targeted cells
- Weeks to months. Gradual restoration of NAD+-dependent pathways
- FOXO4-DRI acts acutely; NAD+ restoration is cumulative
- Regulatory Status
- Research-grade peptide, no FDA approval or clinical trials in humans
- NAD+ precursors (NR, NMN) commercially available as dietary supplements
- NAD+ precursors legally available; FOXO4-DRI restricted to research contexts
- Cost & Accessibility
- Limited synthesis by research peptide suppliers. Typically $200–400 per research vial
- Widely available. NR/NMN supplements range $30–80/month at standard doses
- NAD+ precursors far more accessible for individual use